(Sharecast News) - Hutchmed China said on Monday that several of its oncology medicines would remain covered under China's state reimbursement system next year, while another had been added to a new commercial insurance list, expanding patient access and reinforcing the company's position in the country's multi-layered healthcare market.
The AIM-traded...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE